跳至主要内容
临床试验/NCT00562016
NCT00562016终止3 期

PROTECT II: A Prospective, Multi-center, Randomized Controlled Trial of the IMPELLA RECOVER LP 2.5 System Versus Intra Aortic Balloon Pump (IABP)in Patients Undergoing Non Emergent High Risk PCI

Abiomed Inc.98 个研究点 分布在 3 个国家目标入组 452 人开始时间: 2007年10月最近更新:
适应症

试验速览

阶段
3 期
状态
终止
发起方
Abiomed Inc.
入组人数
452
试验地点
98
主要终点
Composite rate of 10 major adverse events including death; MI;Stroke or TIA; and repeat revascularization.

研究概览

简要总结

The IMPELLA® 2.5 System will be superior to Intra Aortic Balloon Pump in preventing the composite rate of major adverse events during and after the PCI procedure.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Informed consent
  • Subject is indicated for a NON emergent percutaneous treatment of at least on de novo or restenotic lesion in a native coronary vessel or bypass graft.
  • Patient presents with:
  • A compromised Ejection Fraction
  • Intervention on the last patent coronary conduit
  • Intervention on an unprotected left main artery or
  • Patient presenting with triple vessel disease.

排除标准

  • ST elevation M.I.
  • Pre procedure cardiac arrest within 24 hours.
  • Subject in cardiogenic shock

结局指标

主要结局

Composite rate of 10 major adverse events including death; MI;Stroke or TIA; and repeat revascularization.

时间窗: 30 days +/- 10 days

次要结局

  • Maximum CPO decrease from baseline.Rate of in hospital major events compared between the IMPELLA and IABP.(In hospital events)

研究者

发起方
Abiomed Inc.
申办方类型
Industry

研究点 (98)

Loading locations...

相似试验